Recombinant TRAIL ligand and monoclonal agonist antibodies to death receptor (DR4/5) were developed as cancer therapeutics but were found to be clinically ineffective, likely because of widespread resistance to TRAIL-induced apoptosis (Herbst et al, 2010; Holland, 2014). The gene discussed is TNFSF10; the disease is cancer.